These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 27865372)

  • 1. Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study.
    Del Barco Morillo E; Mesía R; Adansa Klain JC; Vázquez Fernández S; Martínez-Galán J; Pastor Borgoñon M; González-Rivas C; Caballero Daroqui J; Berrocal A; Martínez-Trufero J; Vera R; Cruz-Hernández JJ;
    Oral Oncol; 2016 Nov; 62():54-59. PubMed ID: 27865372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
    Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
    Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.
    Wirth LJ; Dakhil S; Kornek G; Axelrod R; Adkins D; Pant S; O'Brien P; Debruyne PR; Oliner KS; Dong J; Murugappan S
    Oral Oncol; 2016 Oct; 61():31-40. PubMed ID: 27688102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Rischin D; Spigel DR; Adkins D; Wein R; Arnold S; Singhal N; Lee O; Murugappan S
    Head Neck; 2016 Apr; 38 Suppl 1():E1756-61. PubMed ID: 26681429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
    Jimeno A; Machiels JP; Wirth L; Specenier P; Seiwert TY; Mardjuadi F; Wang X; Kapp AV; Royer-Joo S; Penuel E; McCall B; Pirzkall A; Clement PM
    Cancer; 2016 Dec; 122(24):3803-3811. PubMed ID: 27525588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
    Soulières D; Faivre S; Mesía R; Remenár É; Li SH; Karpenko A; Dechaphunkul A; Ochsenreither S; Kiss LA; Lin JC; Nagarkar R; Tamás L; Kim SB; Erfán J; Alyasova A; Kasper S; Barone C; Turri S; Chakravartty A; Chol M; Aimone P; Hirawat S; Licitra L
    Lancet Oncol; 2017 Mar; 18(3):323-335. PubMed ID: 28131786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma.
    Shin DM; Khuri FR; Glisson BS; Ginsberg L; Papadimitrakopoulou VM; Clayman G; Lee JJ; Ang KK; Lippman SM; Hong WK
    Cancer; 2001 Apr; 91(7):1316-23. PubMed ID: 11283932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential chemotherapy regimen of induction with panitumumab and paclitaxel followed by radiotherapy and panitumumab in patients with locally advanced head and neck cancer unfit for platinum derivatives. The phase II, PANTERA/TTCC-2010-06 study.
    Martínez-Trufero J; Lozano Borbalas A; Pajares Bernad I; Taberna Sanz M; Ortega Izquierdo E; Cirauqui Cirauqui B; Rubió-Casadevall J; Plana Serrahima M; Ponce Ortega JM; Planas Toledano I; Caballero J; Marruecos Querol J; Iglesias Docampo L; Lambea Sorrosal J; Adansa JC; Mesía Nin R;
    Clin Transl Oncol; 2021 Aug; 23(8):1666-1677. PubMed ID: 33876416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).
    Tahara M; Kiyota N; Yokota T; Hasegawa Y; Muro K; Takahashi S; Onoe T; Homma A; Taguchi J; Suzuki M; Minato K; Yane K; Ueda S; Hara H; Saijo K; Yamanaka T
    Ann Oncol; 2018 Apr; 29(4):1004-1009. PubMed ID: 29408977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.
    Hussain M; Gadgeel S; Kucuk O; Du W; Salwen W; Ensley J
    Cancer; 1999 Dec; 86(11):2364-9. PubMed ID: 10590379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
    Hitt R; Irigoyen A; Cortes-Funes H; Grau JJ; García-Sáenz JA; Cruz-Hernandez JJ;
    Ann Oncol; 2012 Apr; 23(4):1016-22. PubMed ID: 21865152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
    Machiels JP; Haddad RI; Fayette J; Licitra LF; Tahara M; Vermorken JB; Clement PM; Gauler T; Cupissol D; Grau JJ; Guigay J; Caponigro F; de Castro G; de Souza Viana L; Keilholz U; Del Campo JM; Cong XJ; Ehrnrooth E; Cohen EE;
    Lancet Oncol; 2015 May; 16(5):583-94. PubMed ID: 25892145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Shin DM; Glisson BS; Khuri FR; Hong WK; Lippman SM
    Semin Oncol; 1998 Apr; 25(2 Suppl 4):40-4; discussion 45-8. PubMed ID: 9578061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel and cetuximab combination efficiency after the failure of a platinum-based chemotherapy in recurrent/metastatic head and neck squamous cell carcinoma.
    Péron J; Ceruse P; Lavergne E; Buiret G; Pham BN; Chabaud S; Favier B; Girodet D; Zrounba P; Ramade A; Fayette J
    Anticancer Drugs; 2012 Oct; 23(9):996-1001. PubMed ID: 22643048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capecitabine and lapatinib for the first-line treatment of metastatic/recurrent head and neck squamous cell carcinoma.
    Weiss JM; Bagley S; Hwang WT; Bauml J; Olson JG; Cohen RB; Hayes DN; Langer C
    Cancer; 2016 Aug; 122(15):2350-5. PubMed ID: 27197056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients.
    Jiménez B; Trigo JM; Pajares BI; Sáez MI; Quero C; Navarro V; Llácer C; Medina L; Rueda A; Alba E
    Oral Oncol; 2013 Feb; 49(2):182-5. PubMed ID: 23026069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma.
    Shin DM; Glisson BS; Khuri FR; Ginsberg L; Papadimitrakopoulou V; Lee JJ; Lawhorn K; Gillenwater AM; Ang KK; Clayman GL; Callender DL; Hong WK; Lippman SM
    J Clin Oncol; 1998 Apr; 16(4):1325-30. PubMed ID: 9552033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
    Worden FP; Moon J; Samlowski W; Clark JI; Dakhil SR; Williamson S; Urba SG; Ensley J; Hussain MH;
    Cancer; 2006 Jul; 107(2):319-27. PubMed ID: 16779801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma.
    Adamo V; Ferraro G; Pergolizzi S; Sergi C; Laudani A; Settineri N; Alafaci E; Scimone A; Spano F; Spitaleri G
    Oral Oncol; 2004 May; 40(5):525-31. PubMed ID: 15006626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of paclitaxel and cisplatin combination chemotherapy in recurrent or metastatic head and neck cancer.
    Basaran M; Bavbek SE; Güllü I; Demirelli F; Sakar B; Tenekeci N; Altun M; Yalçin S; Onat H
    J Chemother; 2002 Apr; 14(2):207-13. PubMed ID: 12017379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.